欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2002, Vol. 7 ›› Issue (2): 156-158.

• 临床研究 • 上一篇    下一篇

尿激酶治疗急性脑梗死临床研究

王文静, 赵江明, 余锋, 孙柏松, 汪银洲, 朱守政   

  1. 安徽省立医院神经内科, 合肥 230001
  • 收稿日期:2002-02-28 修回日期:2002-03-10 出版日期:2002-04-26 发布日期:2020-11-27
  • 通讯作者: 王文静, 女, 副主任医师, 从事神经内科临床工作及脑血管疾病的防治。Tel:0551-2652797-5159
  • 基金资助:
    1 安徽省卫生厅科研资助项目

Clinical study of urokinase in the treatment of acute infarct

WANG Wen-Jing, ZAO Jian-Ming, YU Feng, SUN Bo-Song, WANG Yin-Zhou, ZHU Shou-Zhen   

  1. Department of Neurology, Anhui Provincial Hospital, Hefei 230001
  • Received:2002-02-28 Revised:2002-03-10 Online:2002-04-26 Published:2020-11-27

摘要: 目的: 探讨尿激酶静脉溶栓治疗急性脑梗死的疗效。方法: 采用尿激酶30 万U 加入0.9 %生理盐水250 ml, 每日静脉滴注, 连续5 d, 改为尿激酶10 万U, 连用5 ~ 10 d。 结果: 神经功能缺损评分:治疗后5 d 与治疗前无明显差异(P>0.05), 治疗后14 d 与治疗前有显著性差异(P<0.05);生活能力状况:治疗后5 d、14 d 与治疗前比较有极显著性差异(P<0.01);临床疗效评定:治疗后5 d 显效率42.86 %, 治疗后14 d 显效率71.43 %, 两组有极显著性差异(P<0.01);纤维蛋白原、全血还原粘度:治疗后5 d、14 d 与治疗前相比均有显著性差异(P<0.01)。结论: 尿激酶静脉溶栓治疗急性脑梗死安全、有效, 方法简便、快捷。严格选择病例, 监测凝血象、血小板等指标, 并发症可避免或减少。

关键词: 尿激酶, 静脉溶栓, 脑梗死

Abstract: AIM: To explore the efficacy of urokinase used intravenously in the treatment of acute infarct. METHODS: Urokinase of 300 thousand units were added to 250ml 0.9 % normal saline intravenously, lasting for 5 days, and then changed to 100 thousand units for 5-10 d.RESULTS: The assessment of neurologic dysfunction as follows:there were no significant difference after 5 day treatment as compared with pretreatment (P> 0.05), and significant difference was noticed after 14 day treatment as compared with pretreatment (P<0.05). The status of life ability as follows:there were much significant difference after 5 day and 14 day treatment as compared with pretreatment (P<0.01).The clinical efficacy:the ratio of showing-effect was 42.86 % after 5 day treatment, and 71.43 % after 14 day treatment, and there were much significantly difference between those two groups.The fibrinogen and blood deoxidized viscosity: there were significantly difference after 5 day and 14 day treatment as compared with pretreatment (P<0.01).CONCLUSION: It is safe, effective, convenient for urokinase to treat acute infarct used intravenously, and the side effects can be avoided or reduced.

Key words: urokinase, thrombolysis, cerebral infarct

中图分类号: